Skye Bioscience, Inc.

NasdaqGM:SKYE Stock Report

Market Cap: US$77.4m

Skye Bioscience Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:SKYE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24SellUS$413,925Punit DhillonIndividual82,910US$5.55
18 Nov 24SellUS$97,722Tu DiepIndividual19,574US$5.55
18 Nov 24SellUS$216,652Kaitlyn ArsenaultIndividual43,396US$5.55
18 Nov 24SellUS$432,061Paul GraysonIndividual86,551US$5.55
13 Sep 24SellUS$1,750,3525AM Venture Management, LLCCompany266,337US$6.60
13 Mar 24BuyUS$4,500,0005AM Venture Management, LLCCompany450,000US$10.00
31 Jan 24BuyUS$12,026,0315AM Venture Management, LLCCompany5,206,074US$2.31

Insider Trading Volume

Insider Buying: SKYE insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of SKYE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders847,4682.79%
Private Companies870,7152.87%
General Public1,411,3774.65%
Hedge Funds1,563,5225.15%
VC/PE Firms11,920,87239.3%
Institutions13,724,33645.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 145.7%.

Top Shareholders

Top 25 shareholders own 89.94% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
32.7%
5AM Venture Management, LLC
9,913,168US$25.3m-2.62%6.4%
6.62%
Versant Venture Management, LLC
2,007,704US$5.1m0%2.27%
5.15%
Sphera Funds Management Ltd
1,563,522US$4.0m20.4%0.78%
4.73%
Baker Bros. Advisors LP
1,434,634US$3.7m187%0.04%
4.33%
Altium Capital Management LP
1,315,146US$3.4m-2.59%1.22%
3.93%
BlackRock, Inc.
1,193,515US$3.0m6.68%no data
3.16%
Schonfeld Strategic Advisors LLC
959,097US$2.4m122%0.02%
2.97%
Ensign Peak Advisors, Inc.
900,000US$2.3m0%no data
2.78%
The Vanguard Group, Inc.
844,173US$2.2m1.27%no data
2.29%
Apposite Capital LLP
694,739US$1.8m0%no data
2.29%
SR One Capital Management, LP
694,739US$1.8m0%0.44%
2.23%
Emerald Health Sciences Inc.
677,633US$1.7m0%no data
2.15%
Driehaus Capital Management LLC
650,758US$1.7m0%0.01%
1.83%
Alyeska Investment Group, L.P.
554,177US$1.4m84.7%0.01%
1.6%
Platinum Investment Management Limited
485,199US$1.2m0%0.05%
1.51%
Point72 Asset Management, L.P.
458,478US$1.2m-23.3%no data
1.32%
AWM Investment Company Inc
400,000US$1.0m0%0.14%
1.3%
Millennium Management LLC
394,386US$1.0m0%no data
1.27%
Geode Capital Management, LLC
385,793US$983.8k4.22%no data
1.17%
State Street Global Advisors, Inc.
354,205US$903.2k7.01%no data
1.14%
Mirae Asset Global Investments Co., Ltd.
344,454US$878.4k0%no data
1.12%
Punit Dhillon
339,166US$864.9k670%no data
0.86%
Paul Grayson
259,701US$662.2k1,010%no data
0.82%
Citadel Advisors LLC
250,013US$637.5k-5.86%no data
0.7%
Velan Capital Partners LP
211,071US$538.2k-50%0.6%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:50
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Skye Bioscience, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC
Jonathan WollebenJMP Securities